Palatin Technologies Supports FDA’s Approval of the First-Ever Treatment for Female Sexual Dysfunction
CRANBURY, N.J., Aug. 18, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential. Palatin’s lead product under development is bremelanotide for the treatment of female sexual dysfunction (FSD). The approval of flibanserin (under development …